Accessibility Menu
X4 Pharmaceuticals logo

X4 Pharmaceuticals(NASDAQ) XFOR

Current Price$3.69
Market Cap$348.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-99%
5 Year-98%
1 Year+157%
1 Month-13%
X4 Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 3.682026-07-20
X4 Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.14%USD 4.052026-07-13
1 month-12.8%USD 4.222026-06-18
3 month-11.75%USD 4.172026-04-21
Year to date-8%USD 4.002025-12-31
1 year+157.34%USD 1.432025-07-18
3 year-93.26%USD 54.602023-07-21
5 year-97.91%USD 175.802021-07-21
Since inception-99.19%USD 455.702019-03-14

X4 Pharmaceuticals Financials at a Glance

Market Cap

$348.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.01M

Net Income (TTM)

-$99.72M

EPS (TTM)

-$4.54

P/E Ratio

-0.81

Dividend

$0.00

Beta (Volatility)

1.34 (Average)

Price

$3.69

Volume

10,855

Open

$3.69

Previous Close

$3.69

Daily Range

$3.63 - $3.75

52-Week Range

$1.35 - $4.83

Estimated Earnings Date

Aug 6, 2026

XFOR News

No articles available.

XFOR: Motley Fool Moneyball Superscore

50

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About X4 Pharmaceuticals

X4 Pharmaceuticals makes a daily pill for people with rare immune system disorders. This medicine helps the body produce more white blood cells to fight off infections. The company serves patients who struggle with frequent health issues due to these rare conditions.

What X4 Makes

  • XOLREMDI: An oral daily medicine approved to treat WHIM syndrome in patients 12 and older; WHIM stands for warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
  • 4WARD Clinical Trial: A Phase 3 study testing the drug mavorixafor for patients with Chronic Neutropenia, which causes abnormally low white blood cell counts.

New Approvals and Partners

  • The European Commission granted marketing approval for XOLREMDI for use in the European Union in April 2026.
  • Partnered with Norgine to develop and sell treatments across Europe, Australia, and New Zealand.
  • Signed a license agreement with Abbisko Therapeutics Co Ltd. for distribution in mainland China and Taiwan.
  • Developing technology under a license with Genzyme Corporation for various therapeutic and diagnostic uses.

A Unique Scientific Focus

X4 focuses on the CXCR4 pathway, which acts as a gatekeeper for releasing white blood cells into the bloodstream. This approach provides an oral treatment for rare blood conditions that previously lacked daily pill options.

The Recent Financial Results

  • Total revenue was $2.7 million in Q1 2026, down 90.6% from Q1 2025.
  • Net loss reached $20.2 million in Q1 2026, turning negative from a $282,000 profit in Q1 2025.
  • Total operating expenses decreased to $23 million in Q1 2026, down from $38.2 million in Q1 2025.
  • Cash and marketable securities totaled $233.7 million as of March 31, 2026.

Bottom Line

X4 is moving from a research-only firm to a commercial business with its first approved drug. It is now focused on selling its treatment and finishing tests for other rare immune conditions.

AI Generated • May 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

45

CEO

Adam R. Craig, MD, PhD

Website

www.x4pharma.com

Headquarters

Boston, MA 02134, US

XFOR Financials

Key Financial Metrics (TTM)

Gross Margin

79.44%

Operating Margin

-1084.38%

Net Income Margin

-1106.30%

Return on Equity

-94.90%

Return on Capital

-32.96%

Return on Assets

-36.90%

Earnings Yield

-1.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$348.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

94.32M

Volume

10.86K

Avg. Volume

644.39K

Financials (TTM)

Gross Profit

$7.16M

Operating Income

-$97.75M

EBITDA

-$89.86M

Operating Cash Flow

-$92.85M

Capital Expenditure

$19.60M

Free Cash Flow

-$73.25M

Cash & ST Invst.

$233.72M

Total Debt

$77.25M

X4 Pharmaceuticals Performance Analysis

X4 Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 2,557,000N/A
20252025-12-31USD 35,113,0001273.2%
X4 Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-93.2%
Q32025-09-30-10.5%
Q42025-12-3145.5%
Q12026-03-315.5%
X4 Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -45.53-61.9%
20232023-12-31USD -17.07-62.5%
20242024-12-31USD -5.59-67.3%
20252025-12-31USD -1.87-66.5%
X4 Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-8775.0%
Q32025-09-3080.1%
Q42025-12-3168.1%
Q12026-03-3127.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.71M

-90.6%

Gross Profit

$2.11M

-91.1%

Gross Margin

77.92%

N/A

Market Cap

$348.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.73M

N/A

Employees

45

N/A

Net Income

-$20.24M

-7277.7%

EBITDA

-$17.87M

-694.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$233.72M

+168.8%

Total Debt

$77.25M

-1.0%

Accounts Receivable

$1.11M

-5.2%

Inventory

$4.64M

+50.1%

Long Term Debt

$76.52M

-0.3%

Short Term Debt

$733.00K

-43.7%

Return on Assets

-36.90%

N/A

Return on Invested Capital

-39.65%

N/A

Free Cash Flow

$0.00

+100.0%

Operating Cash Flow

-$19.60M

-58.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KPTIKaryopharm Therapeutics Inc.
$7.87+5.29%
MRSNMersana Therapeutics, Inc.
$29.08+0.00%
OKUROnKure Therapeutics, Inc.
$4.17+1.21%
KZRKezar Life Sciences, Inc.
$7.29+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$7.66+0.11%
PATHUiPath
$12.04-0.01%
TAT&T
$22.26+0.01%
MARAMara Holdings
$12.25+0.05%

Questions About XFOR

What is the current price of X4 Pharmaceuticals?

X4 Pharmaceuticals is trading at $3.69 per share.

What is the 52-week range for X4 Pharmaceuticals?

Over the past 52 weeks, X4 Pharmaceuticals has traded between $1.35 and $4.83.

How much debt does X4 Pharmaceuticals have?

As of the most recent reporting period, X4 Pharmaceuticals reported total debt of $77.25M.

How much cash does X4 Pharmaceuticals have on hand?

X4 Pharmaceuticals reported $216.91M in cash and cash equivalents in its most recent financial results.

What is X4 Pharmaceuticals’s dividend yield?

X4 Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services